Results of the study showed that administration of imipramine given three weeks following a psilocybin loading dose provided an additional 39% further improvement in depressive behaviors from that of psilocybin loading dose alone. Furthermore, a second administration of imipramine given four weeks after a psilocybin loading dose provided an even greater reduction (45%) in depressive behaviors.
'These results demonstrate that psilocybin has the ability to potentiate the effects of antidepressant medications,' said
While there are a number of available therapies to treat depression, only 60%-70% of patients respond to antidepressant therapy. Of those who do not respond, 10%-30% exhibit treatment-resistant symptoms1, highlighting the need for additional therapeutic options. Further, despite the established importance of treating depression, only 44% of TBI patients with major depressive disorder received antidepressants or counseling2. Of those treated, there is limited evidence supporting the efficacy of antidepressants in the treatment of post-TBI depression3. These new findings suggest that combination therapy could provide more consistent and robust effects over time.
'I'm proud of the work my team has done to continue investigating the full potential of psilocybin alone and in combination with other medications in order to one day provide tailored medication regimens that have an optimized benefit:risk profile,' added
Additionally, The Company has entered into an engagement letter with MDM Worldwide for the provision of market awareness and investor relations services. The engagement has a six-month term at a rate of
About
Contact:
Investor
Email: IR@wesanahealth.com
Phone: 702-329-8038
Forward-Looking Information and Statements
This news release contains 'forward-looking information' within the meaning of applicable securities laws relating to future partnerships, collaborative research and the focus of the Company's business. Any such forward-looking statements may be identified by words such as 'expects', 'anticipates', 'intends', 'contemplates', 'believes', 'projects', 'plans' and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance regarding the participation in, or success of, partnerships or collaborative research or that the Company will continue its business as described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Listing Statement filed on Company's profile on SEDAR at www.sedar.com for information as to the risks and other factors which may affect the Company's business objectives and strategic plans.
(C) 2022 Electronic News Publishing, source